Safety and Immunogenicity of Combined DNA-Polyethylenimine and Oral Bacterial Idiotypic Vaccine for Patients with B-Cell Non-Hodgkin Lymphoma: A Pilot Study

Abstract

We report, in brief, the results of a phase I, non-randomized study of idiotypic DNA vaccination in patients with B-cell non-Hodgkin’s lymphoma (ISRCTN31090206). The DNA sequence of lymphoma-derived immunoglobulin variable regions was used as a tumor-specific antigen fused to the potato virus X coat protein. A conjugate of plasmid DNA with polyethylenimine was used for the intramuscular injections, followed by a boost with an oral live-attenuated Salmonella vaccine carrying the same plasmid. The patients with a complete or partial response to previous chemotherapy received one or two courses of vaccination, including four injections at monthly intervals. The vaccine was well tolerated, with low-grade adverse events. The T-cell immune responses were assessed by ELISpot, at last vaccine, one week and one month post-vaccination, and were detected in 11/14 (78.6%) of the patients. In cases of progression requiring chemotherapy, or the presence of a positive MRD after the first course of vaccination, the patients underwent a second course of vaccination. At the end point, 6/19 vaccinated patients had disease stabilization, while 13/19 were in complete remission. The overall survival was 100% at follow-up, of a median of 2.3 years.

Therapeutic Vaccines for Follicular Lymphoma: A Systematic Review

“…Although Id vaccines have not been shown to be effective against FL, other therapeutic vaccine types are still a focus of research. Thus, the idea of Id vaccines has evolved in the form of an attempt to inject DNA with an encoded Id [ 80 , 81 ]. The peptide vaccine technology is also being actively studied.…”

Design and Immunogenicity of SARS-CoV-2 DNA Vaccine Encoding RBD-PVXCP Fusion Protein

“…However, there is an additional window for DNA vaccine improvement [ 41 , 42 , 43 ]. To deepen the humoral immune response to our DNA SARS-CoV-2 vaccine, we implemented several solutions: (I) fusion of the SARS-CoV-2 antigen to Potato virus X coat protein (PVXCP) to ensure the assembly of VLP and Th1 immune response skewing: (II) selection of RBD as an antigen of SARS-CoV-2 to enhance protection from VOCs and ensure the safety of our SARS-CoV-2 vaccine.…”

Transcriptional Targeting of Dendritic Cells Using an Optimized Human Fascin1 Gene Promoter

“…Based on a deeper understanding of the pathophysiology and the important role of immune dysfunction in cancer development and progression, nucleic acid-based immunotherapeutic approaches have attracted growing interest in recent years [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15]. Hereby, the aims are (i) to modulate the immune system in such a way that it effectively fights the tumor and (ii) to create an immunological memory for long-term protection.…”